| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | C A Blau | |
| C P Miller | |||
| P2860 | cites work | Cellular signaling by fibroblast growth factor receptors | Q24301087 |
| Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity | Q27765263 | ||
| Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression | Q33288270 | ||
| JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells | Q34087180 | ||
| Side effects of retroviral gene transfer into hematopoietic stem cells | Q34168349 | ||
| Pharmacologically regulated cell therapy | Q34225667 | ||
| Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review | Q34286438 | ||
| Controlling Signal Transduction with Synthetic Ligands | Q34306937 | ||
| A chromatin insulator protects retrovirus vectors from chromosomal position effects | Q35198059 | ||
| Erythropoietin receptor mRNA expression in human endothelial cells | Q35208338 | ||
| Growth factor receptors as regulators of hematopoiesis | Q35848814 | ||
| A proliferation switch for genetically modified cells | Q36077799 | ||
| Targeted expansion of genetically modified bone marrow cells | Q36167363 | ||
| The anaemia of cancer: death by a thousand cuts | Q36167596 | ||
| Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study | Q36222669 | ||
| Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice | Q36622808 | ||
| Erythropoietin in cancer: presumption of innocence? | Q36803489 | ||
| Control of myoblast proliferation with a synthetic ligand | Q38297845 | ||
| Functional significance of erythropoietin receptor expression in breast cancer | Q38364203 | ||
| Selection with a regulated cell growth switch increases the likelihood of expression for a linked gamma-globin gene | Q40424440 | ||
| Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma | Q40430272 | ||
| Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells | Q40492460 | ||
| Small-molecule-directed mpl signaling can complement growth factors to selectively expand genetically modified cord blood cells | Q40677385 | ||
| Dimerizer-induced proliferation of genetically modified hepatocytes | Q40739020 | ||
| Receptor specificity in the self-renewal and differentiation of primary multipotential hemopoietic cells. | Q40795297 | ||
| An inducible caspase 9 safety switch for T-cell therapy | Q41768001 | ||
| Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects | Q42829430 | ||
| A bloodless revolution. A growing interest in artificial blood substitutes has resulted in new products that could soon improve transfusion medicine | Q43205596 | ||
| Pharmacologically regulated in vivo selection in a large animal | Q44117631 | ||
| Modulating erythrocyte chimerism in a mouse model of pyruvate kinase deficiency | Q44779183 | ||
| In vivo selection of genetically modified erythroid cells using a jak2-based cell growth switch | Q45036079 | ||
| Pharmacologically regulated regeneration of functional human pancreatic islets. | Q45178243 | ||
| In vivo selection using a cell-growth switch | Q45870526 | ||
| T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients | Q45876112 | ||
| Anatomical compartments modify the response of human hematopoietic cells to a mitogenic signal | Q46864865 | ||
| Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. | Q47438492 | ||
| Erythropoietin regulates tumour growth of human malignancies | Q48280802 | ||
| Expression of erythropoietin receptor splice variants in human cancer. | Q51835125 | ||
| Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. | Q53204531 | ||
| Relation of Erythropoietin and Erythropoietin Receptor Expression to Hypoxia and Anemia in Head and Neck Squamous Cell Carcinoma | Q58211963 | ||
| Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo | Q59067674 | ||
| Preclinical and Clinical Studies with Recombinant Human Basic Fibroblast Growth Factor | Q67847584 | ||
| Hypotensive activity of fibroblast growth factor | Q68066299 | ||
| Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers | Q74370488 | ||
| Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial | Q79202551 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 759-764 | |
| P577 | publication date | 2008-03-20 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Using gene transfer to circumvent off-target effects | |
| P478 | volume | 15 |
| Q34755217 | A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy |
| Q35056286 | A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor |
| Q33970635 | Catch and Release: Photocleavable Cationic Diblock Copolymers as a Potential Platform for Nucleic Acid Delivery |
| Q28544690 | In vivo regulation of erythropoiesis by chemically inducible dimerization of the erythropoietin receptor intracellular domain |
| Q35086136 | Long-term regulation of genetically modified primary hematopoietic cells in dogs |
Search more.